NASDAQ:ZLAB Zai Lab (ZLAB) Stock Price, News & Analysis $22.36 -0.68 (-2.95%) Closing price 04:00 PM EasternExtended Trading$22.14 -0.22 (-0.96%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Zai Lab Stock (NASDAQ:ZLAB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Zai Lab alerts:Sign Up Key Stats Today's Range$22.14▼$22.8550-Day Range$22.04▼$27.0052-Week Range$15.96▼$27.50Volume648,511 shsAverage Volume1.06 million shsMarket Capitalization$2.54 billionP/E RatioN/ADividend YieldN/APrice Target$37.25Consensus RatingModerate Buy Company Overview Zai Lab Ltd. (NASDAQ:ZLAB) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. Its research and development activities have included oncology, autoimmune and inflammatory disorders, neuroscience, infectious diseases and other areas of significant unmet medical need. Founded in 2014, Zai Lab has built its business through a combination of internally developed programs and licensing or collaboration agreements with international pharmaceutical and biotechnology companies. Its portfolio has included medicines such as ZEJULA (niraparib) for certain ovarian cancers, QINLOCK (ripretinib) for gastrointestinal stromal tumors, and anti-infective products including XERAVA (eravacycline) and NUZYRA (omadacycline), subject to applicable approvals and commercial arrangements. The company primarily serves patients in Greater China, including mainland China, Hong Kong and Macau, while pursuing selected global development and commercialization opportunities. Zai Lab operates research, clinical development and commercial activities across China and maintains international collaborations to expand access to innovative therapies. Samantha Du, who founded Zai Lab, serves as the company’s chairperson and chief executive officer. The company continues to advance a pipeline of internally discovered and partnered candidates through clinical development and regulatory review.AI Generated. May Contain Errors. Read More Zai Lab Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreZLAB MarketRank™: 2.27601342628 of 5 starsZai Lab scored higher than 46% of companies evaluated by MarketBeat, and ranked 640th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingZai Lab has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialZai Lab has a consensus price target of $37.25, representing about 66.6% upside from its current price of $22.36.Amount of Analyst CoverageZai Lab has only been the subject of 3 research reports in the past 90 days.Read more about Zai Lab's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Zai Lab are expected to grow in the coming year, from ($2.37) to ($2.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zai Lab is -13.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zai Lab is -13.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZai Lab has a P/B Ratio of 3.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Zai Lab's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.17% of the float of Zai Lab has been sold short.Short Interest Ratio / Days to CoverZai Lab has a short interest ratio ("days to cover") of 11.28, which indicates bearish sentiment.Change versus previous monthShort interest in Zai Lab has recently increased by 23.69%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZai Lab does not currently pay a dividend.Dividend GrowthZai Lab does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment-0.11 News SentimentZai Lab has a news sentiment score of -0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Zai Lab this week, compared to 3 articles on an average week.Search Interest4 people have searched for ZLAB on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows1 people have added Zai Lab to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Zai Lab insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $235,145.00 in company stock.Percentage Held by Insiders4.88% of the stock of Zai Lab is held by insiders.Percentage Held by Institutions41.65% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Zai Lab's insider trading history. Receive ZLAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZLAB Stock News HeadlinesZai Lab Limited (ZLAB) Discusses Phase 1 Study Results of DLL3-Targeted ADC ZL-1310 in Small Cell Lung Cancer - SlideshowOctober 27 at 7:03 PM | seekingalpha.comZai Lab (NASDAQ: ZLAB) agrees to $250 million private placement financingOctober 26 at 5:03 AM | americanbankingnews.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 29 at 1:00 AM | Weiss Ratings (Ad)Zai Lab to Privately Place $250 Million in ADRs to Fund Drug ResearchOctober 23, 2026 | finance.yahoo.comZai Lab Says Zoci Plus Atezolizumab Improves Response Rate in Phase 1 Lung Cancer TrialOctober 23, 2026 | finance.yahoo.comZai Lab Limited (ZLAB) Discusses Phase 1 Study Results of DLL3-Targeted ADC ZL-1310 in Small Cell Lung Cancer TranscriptOctober 23, 2026 | seekingalpha.comZai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung CancerOctober 23, 2026 | businesswire.comZai Lab Announces $250 Million Private PlacementOctober 22, 2026 | businesswire.comSee More Headlines ZLAB Stock Analysis - Frequently Asked Questions How have ZLAB shares performed this year? Zai Lab's stock was trading at $17.64 on January 1st, 2026. Since then, ZLAB shares have increased by 26.8% and is now trading at $22.36. How were Zai Lab's earnings last quarter? Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) released its quarterly earnings results on Tuesday, June, 30th. The company reported ($0.50) earnings per share for the quarter. The company had revenue of $106.31 million for the quarter. Zai Lab had a negative trailing twelve-month return on equity of 27.43% and a negative net margin of 41.86%. When did Zai Lab IPO? Zai Lab (ZLAB) raised $142 million in an initial public offering on Wednesday, September 20th 2017. The company issued 8,333,333 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO. Who are Zai Lab's major shareholders? Zai Lab's top institutional shareholders include WealthPlan Investment Management LLC (0.03%), China Universal Asset Management Co. Ltd. and Mirae Asset Global Investments Co. Ltd.. Insiders that own company stock include Ying Du, Joshua L Smiley, Harald Reinhart, Rafael Amado, Richard Gaynor, William Lis, Yajing Chen and Frazor Titus Edmondson III. View institutional ownership trends. How do I buy shares of Zai Lab? Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zai Lab own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zai Lab investors own include Alibaba Group (BABA), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Tesla (TSLA), PayPal (PYPL) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings6/30/2026Today10/29/2026Next Earnings (Estimated)11/05/2026Study update11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ZLAB's financial health is in the Green zone, according to TradeSmith. ZLAB has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ZLAB CIK1704292 Webwww.zailaboratory.com Phone862161632588Fax86-21-6163-2570Employees1,784Year Founded2014Price Target and Rating Average Price Target for Zai Lab$37.25 High Price Target$45.00 Low Price Target$32.00 Potential Upside/Downside+66.6%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$175.54 million Net Margins-41.86% Pretax Margin-42.42% Return on Equity-27.43% Return on Assets-16.72% Debt Debt-to-Equity RatioN/A Current Ratio2.13 Quick Ratio1.92 Sales & Book Value Annual Sales$460.16 million Price / Sales5.53 Cash FlowN/A Price / Cash FlowN/A Book Value$6.39 per share Price / Book3.50Miscellaneous Outstanding Shares113,780,000Free Float108,230,000Market Cap$2.54 billion OptionableOptionable Beta0.73 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ZLAB) was last updated on 10/29/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...The TradingPub | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | SponsoredElon Musk's Intel Deal Already Jumped 177 Percent This YearElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's ...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zai Lab Limited Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Zai Lab With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
